Category Research

Exicure

Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment

Exicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company advancing novel small molecule therapeutics for immuno-oncology and hematological malignancies, announced a significant milestone today in its ongoing Phase 2 clinical…

Read MoreExicure Approaches Phase 2 Completion for GPC-100 in Multiple Myeloma Treatment
Exicure

Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company focused on developing innovative therapeutics targeting diseases with high unmet medical needs, announced significant updates today regarding its lead investigational…

Read MoreExicure Announces Plans for New Clinical Trial in Acute Myeloid Leukemia (AML)
Pregnancy

Biologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients

Biologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients Landmark Clinical Trial Finds Certolizumab Significantly Improves Pregnancy Outcomes in Women with Antiphospholipid Syndrome In a groundbreaking advancement for maternal-fetal medicine and autoimmune disease treatment, a phase 2 clinical trial co-led…

Read MoreBiologic Therapy Boosts Pregnancy Outcomes in High-Risk APS Patients
Antibiotic

Two Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients

Two Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients In a significant advancement for infectious disease care and antibiotic stewardship, two large-scale clinical trials funded by the National Institutes of Health (NIH) have demonstrated that integrating real-time,…

Read MoreTwo Major Trials Identify Effective Antibiotic Selection Method for Hospitalized Infection Patients
LifeMine

LifeMine Doses First Participant in Phase 1 Trial of Novel Immunosuppressive LIFE-001

LifeMine Doses First Participant in Phase 1 Trial of Novel Immunosuppressive LIFE-001 LifeMine Therapeutics Inc., a clinical-stage biopharmaceutical company redefining small molecule discovery through its proprietary genomic search platform, has officially dosed the first participant in a Phase 1 clinical…

Read MoreLifeMine Doses First Participant in Phase 1 Trial of Novel Immunosuppressive LIFE-001
Verge Genomics

Verge Genomics Identifies Digital Biomarkers for Early ALS Progression in VRG50635 Trial

Verge Genomics Identifies Digital Biomarkers for Early ALS Progression in VRG50635 Trial Verge Genomics, a trailblazer in AI-powered drug discovery and development, today announced pivotal findings that could reshape the design and execution of clinical trials for neurodegenerative diseases. In…

Read MoreVerge Genomics Identifies Digital Biomarkers for Early ALS Progression in VRG50635 Trial
Flatiron Health

Flatiron Health Partners with Massive Bio to Strengthen Patient Identification and Services

Flatiron Health Partners with Massive Bio to Strengthen Patient Identification and Services In a strategic move poised to reshape the landscape of oncology clinical research, Flatiron Health, a leading health technology company dedicated to transforming clinical trials through the integration…

Read MoreFlatiron Health Partners with Massive Bio to Strengthen Patient Identification and Services